Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the fully humanised immunoglobulin G4 (IgG4) antibody, imsidolimab ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization of imsidolimab, which has successfully completed two ...

Under the terms of the agreement, Vanda will make to Anaptys an upfront payment of $10M and a $5M payment for existing drug supply. Anaptys is also eligible to receive up to $35M for future ...

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers ...

AnaptysBio also reported a strong cash position of $420 million, projecting a cash runway through 2027. Additionally, the company entered a licensing agreement with Vanda Pharmaceuticals for ...

https://www.tipranks.com/news/the-fly/medtronic-price-target-raised-to-93-from-89-at-truist Truist notes that AnaptysBio (ANAB) reported the “much anticipated ...

(RTTNews) - AnaptysBio, Inc. (ANAB) on Monday announced that its Board of Directors has authorized a stock repurchase plan under which the company may repurchase up to $75 million of its ...

Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

AnaptysBio, Inc. has announced a Stock Repurchase Plan allowing for the buyback of up to $75 million of its common stock. As of the end of 2024, the company reports having over $420 million in ...